TMEM106B a Novel Risk Factor for Frontotemporal Lobar Degeneration
- First Online:
- Cite this article as:
- van der Zee, J. & Van Broeckhoven, C. J Mol Neurosci (2011) 45: 516. doi:10.1007/s12031-011-9555-x
- 317 Views
Recently, the first genome-wide association (GWA) study in frontotemporal lobar degeneration (FTLD) identified common genetic variability at the TMEM106B gene on chromosome 7p21.3 as a potential important risk-modifying factor for FTLD with pathologic inclusions of TAR DNA-binding protein (FTLD-TDP), the most common pathological subtype in FTLD. To gather additional evidence for the implication of TMEM106B in FTLD risk, multiple replication studies in geographically distinct populations were set up. In this review, we revise all recent replication and follow-up studies of the FTLD-TDP GWA study and summarize the growing body of evidence that establish TMEM106B as a bona fide risk factor for FTLD. With the TMEM106B gene, a new player has been identified in the pathogenic cascade of FTLD which could hold important implications for the future development of disease-modifying therapies.
KeywordsFrontotemporal lobar degenerationFTLDFTLD-TDPTMEM106BGenome-wide association studyGenetic risk factor
In an attempt to resolve the missing heritability in neurodegenerative diseases, genetic research has shifted focus from linkage and positional cloning studies in multigenerational families for the identification of rare causal genes, towards genome-wide association (GWA) studies for the identification of more common genetic risk factors. In ever-growing sample sizes, these studies have become increasingly successful, e.g., in amyotrophic lateral sclerosis (ALS, (van Es et al. 2009)), Parkinson's disease (Simon-Sanchez et al. 2009), and Alzheimer's disease (Lambert et al. 2009; Harold et al. 2009). However, in FTLD research, likely due to the higher familial load in this dementia subtype (up to 30–40% of patients have a positive family history), the first GWA study was only recently undertaken. In FTLD, the known causal genes explain 10% to 20% of all patients. In our Flanders–Belgian FTLD cohort (n = 315) for example, we have observed 35 patients with a mutation in GRN (n = 13), MAPT (n = 4), VCP (n = 2), CHMP2B (n = 1), FUS (n = 1), or PSEN1 (n = 1) representing 11% of the total population and 29% of familial patients. Notwithstanding, a significant fraction of patients, including the familial patients, remains unresolved. In the beginning of 2010, the results of the first GWA study in FTLD were published (Van Deerlin et al. 2010). Although there had been skepticism about the success of such a GWA study in FTLD, because of its inherent clinical and pathologic heterogeneity, this study ensured its success by including only patients with FTLD-TDP pathology. Despite having to pay a penalty for more limited sample size, this approach dramatically reduced the genetic heterogeneity of their study population and thereby their power to identify disease association. In an international collaboration including 45 sites from 11 countries, DNA from 515 patients with confirmed FTLD-TDP pathology, either by histopathology or presence of a GRN mutation, was collected. Comparison of the FTLD-TDP patients to 2,509 control individuals identified three single-nucleotide polymorphisms (SNPs) with genome-wide significance (rs1020004, rs6966915, and rs1990622). The three top SNPs mapped to a single linkage disequilibrium (LD)-block of 68 kb at 7p21.3 encompassing the gene coding for TMEM106B, an uncharacterized transmembrane protein, and two other genes at the rim of the associated region, scinderin (SCIN) and ADP-ribosylation factor-like 4A (ARL4A) (Van Deerlin et al. 2010). The association was strongest in carriers of pathogenic GRN mutations, suggesting a disease modifying effect of TMEM106B SNPs in GRN mutation carriers. Moreover, expression studies in brain demonstrated that TMEM106B is expressed in frontal cortex (heavily affected in FTLD) and is significantly increased in FTLD-TDP patients compared to unaffected individuals, providing initial biological evidence for TMEM106B as a novel risk factor for FTLD-TDP.
Allelic association of TMEM106B in the Flanders–Belgian clinical FTLD cohort
Minor allele frequency
OR [95% CI]
Patients (n = 288)
Controls (n = 595)
Genotypic association of TMEM106B in the Flanders–Belgian clinical FTLD cohort
OR [95% CI]
Patients (n = 288)
Controls (n = 595)
In addition to the Flanders–Belgian replication study, other replication studies of TMEM106B are being reported in geographically distinct populations. Whereas our case–control study only included ten unrelated patients with a GRN mutation, Finch and colleagues (2011) focused on the risk-modifying effect of TMEM106B on GRN-related FTLD. In contrast to our findings, in 482 clinical FTLD patients without GRN mutations compared to 822 control individuals, no association with the TMEM106B SNPs was observed. However, in a relatively small sample of 78 GRN-positive patients, the TMEM106B variants appeared to be highly significantly associated, with homozygotes of the minor alleles decreased to 3% of patients versus 19% of controls (p = 0.009) (Finch et al. 2011). Finch et al. (2011) attributed this to a protective effect of the TMEM106B SNPs specific to GRN mutation carriers. We observed a similar trend in the subset of 97 familial Flemish patients (counting only ten GRN mutation carriers). Here, homozygotes of the rs1990622 protective C allele were decreased to 8% (n = 7) in patients (compared to 13% in the total patient population) versus 18% in controls, with a reduced disease risk of 68% (ORCC = 0.32, [95% CI 0.14–0.73], p = 0.007). As both in the original GWA study by Van Deerlin et al. and the replication study by Finch et al., the effect was clearly most pronounced in GRN mutation carriers; it is likely that the TMEM106B protective effect is strong in GRN-related FTLD. However, our data seem to indicate that although the effect is clearly present in the GRN-positive patients, it is not limited to GRN-related FTLD. The higher genetic load in familial patients is probably at the basis of the observed stronger genetic association. Although we have to be mindful of over-stratifying the cohorts in, e.g., subsets of familial patients or of GRN-positive patients, as this may result in small, statistically less reliable sample sizes in which the allele frequencies may be skewed.
In a first step to find biological evidence for the association of TMEM106B and FTLD-TDP, Van Deerlin et al. (2010) were able to demonstrate an up to 2.5 increase of TMEM106B expression in brain frontal cortex of FTLD-TDP patients compared to controls. This led them to suggest that TMEM106B confers FTLD-TDP risk by increased expression. Obtaining high-quality RNA from a significant number of brain samples is challenging. In our study, we were able to analyze brain frontal cortex samples from 11 FTLD-TDP patients and 12 control individuals. In this sample set, we observed no increased TMEM106B expression in FTLD-TDP patients compared to controls. Although our number of brain samples was limited, it was in the same range of the original study (n = 25) (van der Zee et al. 2011). Furthermore, in brain frontal cortex cDNA of 40 unaffected controls, Cruchaga et al. (2011) also failed to find evidence of correlation between TMEM106B expression and genotype. Expression analyses of larger number of patient and control brains will be vital to resolve whether or not TMEM106B pathogenesis is mediated by variable gene expression.
Ever since the identification of GRN as a major disease gene in FTLD, researchers have speculated about the biological basis of the observed variability in onset age associated with GRN mutations. GRN mutations lead to FTLD through haploinsufficiency; still, onset age is highly variable within and between families and ranges from mid-forties to mid-seventies (Cruts and Van Broeckhoven 2008). Furthermore, mutation carriers who died without symptoms in their 80s have been reported. This strongly suggests that other genes and/or environmental factors affect onset age in GRN-related FTLD. Moreover, identification of such genetic modifiers may expose valuable molecular targets for disease-modifying therapies. It is in this light that Cruchaga and colleagues (2011) hypothesized that TMEM106B variants might explain (part of) this phenotypic variability. They analyzed 27 symptomatic and 23 presymptomatic GRN mutation carriers from four previously reported GRN-loss of function (LOF) families (HDDD1 - Ala237fs, FD1 - Ala237fs, HDDD2 - Ala9Asp, and the Karolinska family - Gly35fs) and observed a strong association between rs1990622 and disease onset, with a mean decrease in onset age of 13 years for patients homozygote for the risk allele (T) compared to patients with one or two copies of the minor protective allele (C) (Cruchaga et al. 2011). Moreover, they additionally demonstrated a correlation between rs1990622 and GRN plasma levels in 73 healthy individuals (Cruchaga et al. 2011). In a much more extended control series, Finch and coworkers (2011) also considered if associated TMEM106B variants modified disease penetrance in GRN-positive FTLD by modulating GRN protein levels. In 1,013 plasma samples from healthy controls, they showed that the TMEM106B SNPS are associated with a modest but significant increase in GRN protein levels. The findings on onset age by Cruchaga et al. were not in line with what we observed in the extended Flanders–Belgian FTLD founder pedigree segregating the GRN IVS1+5G>C splice donor site mutation (Cruts et al. 2006; van der Zee et al. 2011). The founder pedigree consists of 226 clinically well-documented individuals, who are related in at least seven generations, including 41 patients and at least 37 asymptomatic at risk mutation carriers. Onset age among patients ranges from 45 to 76 years, and at least 7 mutation carriers were still free of symptoms while older than the mean onset age in the pedigree, including an obligate mutation carrier who died at 81 years of age (Cruts et al. 2006; Brouwers et al. 2007). Onset age analysis in this powerful multigeneration pedigree demonstrated no correlation of the TMEM160B variants rs1040002 and rs1990622 with onset age, failing to explain the >30 years onset age range in the GRN IVS1 + 5 G > C carriers (van der Zee et al. 2011). Therefore, in the Flanders–Belgian GRN founder family, we see no evidence for a disease-modifying effect of TMEM106B. Possibly multiple GRN-LOF modifiers exist and another modifying factor is contributing to the phenotype in our founder family compared to the other GRN-LOF families. Although the control studies by Finch and Cruchaga seem to indicate that TMEM106B variants influence GRN protein levels and thereby disease penetrance in GRN-related FTLD, a direct correlation between GRN plasma levels and onset age has not been demonstrated to date. Also, the observed increase in GRN protein levels in healthy homozygous carriers of the protective TMEM106B alleles seems very limited to be able to rescue the extreme drop in GRN levels that is observed in GRN-LOF patients (Ghidoni et al. 2008; Finch et al. 2009; Sleegers et al. 2009; Sleegers et al. 2010). Further more elaborate studies in affected versus unaffected GRN-LOF mutation carriers will be required to gather conclusive evidence for whether or not TMEM106B is able to modify disease penetrance and onset age in GRN mutation carriers by modulating GRN plasma levels.
In a follow-up study by the principal authors of the FTLD-TDP GWA study, Vass et al. (2010) investigated whether the FTLD-TDP associated TMEM106B risk genotypes could also contribute to the risk and disease presentation of ALS. Although they could not demonstrate association between the TMEM106B genotypes and ALS, the protective allele of rs1990622 did appear to be associated with preserved cognition in ALS patients. Correlation with cognitive performance was strong as measured by the phonemic verbal fluency test, but could however not be confirmed by other cognitive tests. Their findings, although preliminary, are of interest in light of the TDP-43 proteinopathy spectrum that binds FTLD and ALS. It appears that TMEM106B, as a risk factor for FTLD, is also able to influence cognitive impairment in ALS patients. Along this line, Rollinson et al. (2011) set out to replicate not only the genome-wide associated TMEM106B locus at 7p21.3 but also investigated the other suggestive loci identified by the FTLD-TDP GWAS on chromosomes 1, 8, 9, 10, and 11 that reached sub-threshold significance. In a clinical cohort of 470 British patients, replication at chromosomes 1, 7, 8, 9, 10, and 11 was negative. However, when restricting the analysis to the 84 patients with an FTLD-ALS phenotype, convincing evidence for association was found at multiple SNPs on the 9p locus, a locus well known to be linked to multiple FTLD-ALS families (ALSFTD2, (Boxer et al. 2011; Gijselinck et al. 2010; Le Ber et al. 2009; Luty et al. 2008; Valdmanis et al. 2008; Morita et al. 2006; Vance et al. 2006)) as well as being associated to ALS risk (van Es et al. 2009). This study again suggests that FTLD and ALS share a common genetic basis that also includes shared genetic risk factors.
In conclusion, although the multiple replication and follow-up studies differed somewhat in research focus and therefore resulting observations, overall, the findings from the different research groups in geographically distinct populations seem to point out TMEM106B as bona fide risk factor for FTLD. Further research is needed to learn whether T185S, variable gene expression or another mechanism contributes to the disease biology driving the association of TMEM106B with FTLD. Hereto, targeted resequencing of the TMEM106B genomic region may uncover other potential functional variants that explain the association. Elucidating the biological pathways through which TMEM106B is able to affect disease risk of FTLD, whether or not by influencing GRN protein levels, will shed new light on the pathogenic cascade of FTLD-TDP and FTLD in general. These novel insights will bring us one step closer in understanding this devastating dementia disorder and in developing targeted therapeutic strategies.
Research in the authors' research group was funded in part by the Interuniversity Attraction Poles (IAP) program P6/43 of the Belgian Federal Science Policy office; the Foundation for Alzheimer Research (SAO/FRMA); the Association for Frontotemporal Dementias (AFTD); the Medical Foundation Queen Elisabeth; a Methusalem excellence grant of the Flemish Government; the Research Foundation Flanders (FWO); the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-V); and the Special Research Fund (BOF) of the University of Antwerp, Belgium. The FWO provided a postdoctoral fellowship to [J.v.d.Z.].
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.